Diag2Tec delivers advanced transcriptomic profiling services using bulk and single-cell RNA sequencing to comprehensively characterize tumor cells and their microenvironment. Our analyses provide deep, high-resolution insights into disease biology, treatment-induced pressures, and tumor resistance mechanisms.
Diag2Tec delivers advanced transcriptomic profiling services using bulk and single-cell RNA sequencing to comprehensively characterize tumor cells and their microenvironment. Our analyses provide deep, high-resolution insights into disease biology, treatment-induced pressures, and tumor resistance mechanisms. Gene expression profiling and pathway activation analyses in sensitive and resistant cells enable the selection of optimal therapeutic combinations. The depth of our RNA sequencing datasets allows the detection of recurrent mutations and cytogenetic abnormalities frequently found in hematologic malignancies. The integration of these data with patented methodologies supports the identification of prognostic and predictive biomarkers, contributing to precision medicine strategies and data-driven decision-making.
Biomarker Discovery and Translational Insights
Our analyses support:
- Identification of prognostic biomarkers associated with patient outcomes
- Discovery of predictive biomarkers of response to therapies
- Characterization of treatment pressure and tumor resistance mechanisms
- Identification of gene signatures associated to drug sensitivity/resistance
- Integration with biological and functional assay data
- Support for the rational selection of combination therapies
Deliverables
High-quality, decision-ready data packages including comprehensive reports, as well as raw, quality-controlled, and processed datasets. Secure data transfer and access are ensured through cloud-based infrastructure (AWS).